To the Editor:Due to the highly complex nature of intensity-modulated radiotherapy(IMRT)planning and delivery,patient specific quality assurance(PSQA)should be implemented to assure the reliability of treatment delive...To the Editor:Due to the highly complex nature of intensity-modulated radiotherapy(IMRT)planning and delivery,patient specific quality assurance(PSQA)should be implemented to assure the reliability of treatment delivery and improve the treatment efficacy.展开更多
Immunotherapy,as one of the major strategies for cancer treatment,has shown promising efficacy in cancer treatment by the clinical application of programmed cell death protein-1/programmed cell death-ligand 1(PD-1/PD-...Immunotherapy,as one of the major strategies for cancer treatment,has shown promising efficacy in cancer treatment by the clinical application of programmed cell death protein-1/programmed cell death-ligand 1(PD-1/PD-L1)antibodies which have demonstrated a significant prolongation in the survival time of melanoma,lung,and liver cancer patients.[1–3].Meanwhile,the clinical observation of partial responses in unirradiated lesions after radiotherapy,termed as abscopal effect,has gradually attracted a lot of attention and has inspired oncologists to combine stereotactic radiotherapy(SABR)with immunotherapy for improving clinical outcomes.It is the abscopal effect phenomenon that crucially determines the anti-tumor efficiency of SABR and immune checkpoint inhibitors combination strategy[4].However,due to the short application time and limited experience of the clinical utilization of SABR and anti-PD-1/PD-L1 combination therapy,there are plenty of theoretical and practical issues that need to be systematically discussed,including the mechanisms underlying an abscopal effect,the efficacy and toxicity of combination therapy,and the validity or reliability of corresponding clinical trials.Here,we reviewed previous landmark reports and summarized the research progress of SABR combined with anti-PD-1/PLD-1 therapy to improve the understanding on abscopal effect.展开更多
To investigate the feasibility and early efficacy of 3D-printed vertebral body implantation combined with robotic radiosurgery in the treatment of spinal tumors.This study included 14 patients with spinal tumors from ...To investigate the feasibility and early efficacy of 3D-printed vertebral body implantation combined with robotic radiosurgery in the treatment of spinal tumors.This study included 14 patients with spinal tumors from December 2017 to June 2018.Before surgery,all patients were subjected to CT scan and 3D data of the corresponding vertebral segments were collected.Titanium alloy formed 3D-printed vertebral body implantation and robotic stereotactic radiotherapy were performed because of the risk of postoperative residual,high risk of recovery,or recurrence after surgery.The main outcomes included the remission of symptoms,vertebral body stability,robotic stereotactic surgical precision,and local tumor control.All patients received complete and successful combination therapy,and all healed primarily without complications.The error of the coverage accuracy for robotic radiosurgery was less than 0.5 mm,and the error of the rotation angle was less than 0.5.The therapeutic toxicity was limited(mainly in grades 1–2),and adverse events were uncommon.The evaluation of vertebral body stability and histocompatibility for all patients met the postoperative clinical requirements.For patients with post spinal injury,the pain symptoms were reduced or disappeared(93%),and nerve function was improved or even recovered after treatment(100%).During our follow-up period,most tumors were locally well controlled(93%).3D-printed vertebral body implantation combined with robotic radiosurgery may offer a new treatment of spinal tumors.Chinese clinical trial registry:ChiCTR-ONN-17013946.展开更多
基金National Key Research and Development Program of China(Nos.2021YFE0202500 and 2019YFF01014403)Beijing Municipal Commission of Science and Technology Collaborative Innovation Project(No.Z221100003522028)+1 种基金the National Natural Science Foundation of China(Nos.11735003,11975041,and 11961141004)the fundamental Research Funds for the Central Universities.
文摘To the Editor:Due to the highly complex nature of intensity-modulated radiotherapy(IMRT)planning and delivery,patient specific quality assurance(PSQA)should be implemented to assure the reliability of treatment delivery and improve the treatment efficacy.
基金This research was funded by key clinical projects of Peking University Third Hospital(Peking University talent introduction fund,BYSY2017030).
文摘Immunotherapy,as one of the major strategies for cancer treatment,has shown promising efficacy in cancer treatment by the clinical application of programmed cell death protein-1/programmed cell death-ligand 1(PD-1/PD-L1)antibodies which have demonstrated a significant prolongation in the survival time of melanoma,lung,and liver cancer patients.[1–3].Meanwhile,the clinical observation of partial responses in unirradiated lesions after radiotherapy,termed as abscopal effect,has gradually attracted a lot of attention and has inspired oncologists to combine stereotactic radiotherapy(SABR)with immunotherapy for improving clinical outcomes.It is the abscopal effect phenomenon that crucially determines the anti-tumor efficiency of SABR and immune checkpoint inhibitors combination strategy[4].However,due to the short application time and limited experience of the clinical utilization of SABR and anti-PD-1/PD-L1 combination therapy,there are plenty of theoretical and practical issues that need to be systematically discussed,including the mechanisms underlying an abscopal effect,the efficacy and toxicity of combination therapy,and the validity or reliability of corresponding clinical trials.Here,we reviewed previous landmark reports and summarized the research progress of SABR combined with anti-PD-1/PLD-1 therapy to improve the understanding on abscopal effect.
基金This research was funded by key clinical projects of Peking University Third Hospital(Peking University talent introduction fund,BYSY2017030).
文摘To investigate the feasibility and early efficacy of 3D-printed vertebral body implantation combined with robotic radiosurgery in the treatment of spinal tumors.This study included 14 patients with spinal tumors from December 2017 to June 2018.Before surgery,all patients were subjected to CT scan and 3D data of the corresponding vertebral segments were collected.Titanium alloy formed 3D-printed vertebral body implantation and robotic stereotactic radiotherapy were performed because of the risk of postoperative residual,high risk of recovery,or recurrence after surgery.The main outcomes included the remission of symptoms,vertebral body stability,robotic stereotactic surgical precision,and local tumor control.All patients received complete and successful combination therapy,and all healed primarily without complications.The error of the coverage accuracy for robotic radiosurgery was less than 0.5 mm,and the error of the rotation angle was less than 0.5.The therapeutic toxicity was limited(mainly in grades 1–2),and adverse events were uncommon.The evaluation of vertebral body stability and histocompatibility for all patients met the postoperative clinical requirements.For patients with post spinal injury,the pain symptoms were reduced or disappeared(93%),and nerve function was improved or even recovered after treatment(100%).During our follow-up period,most tumors were locally well controlled(93%).3D-printed vertebral body implantation combined with robotic radiosurgery may offer a new treatment of spinal tumors.Chinese clinical trial registry:ChiCTR-ONN-17013946.
